Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pagel

Showing results (201-210 of 246) with videos related to

Pageof 25
Sort By:
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Journal of Primary Care & Community Health|March 25, 2025
Implementation of a Multicancer Detection (MCD) Test in a Tertiary Referral Center in Asymptomatic Patients: An 18-Month Prospective Cohort StudyRyan T Hurt, Aditya K Ghosh, Brian M Dougan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Molecular Cancer Therapeutics|October 21, 2020
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTAJohnnie J Orozco, Aimee L Kenoyer, Yukang Lin, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.
Pageof 25

Showing results (201-210 of 246) with videos related to

Sort By:
Pageof 25
British Journal of Haematology|July 9, 2013
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemiaFabiana Ostronoff, Megan Othus, Hagop M Kantarjian, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
Journal of Primary Care & Community Health|March 25, 2025
Implementation of a Multicancer Detection (MCD) Test in a Tertiary Referral Center in Asymptomatic Patients: An 18-Month Prospective Cohort StudyRyan T Hurt, Aditya K Ghosh, Brian M Dougan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2019
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic LeukemiaJeff P Sharman, Steven E Coutre, Richard R Furman, et al.
Molecular Cancer Therapeutics|October 21, 2020
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and <sup>90</sup>Y-DOTAJohnnie J Orozco, Aimee L Kenoyer, Yukang Lin, et al.
Leukemia|April 28, 2021
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignanciesRichard R Furman, John C Byrd, Roger G Owen, et al.
Journal of Hematology & Oncology|April 26, 2026
Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2Javier Muñoz, Frederick L Locke, Patrick M Reagan, et al.
Haematologica|June 27, 2012
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.
Pageof 25